ArticleMolecular cancer research : MCR2017
Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Rewiring KRAS-driven cancers through the ubiquitin-proteasome system: therapeutic opportunities with a focus on deubiquitinase.Experimental & molecular medicine · 2026Review
- Article
- Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.bioRxiv : the preprint server for biology · 2026Article
- Review
- Role of the USP family in autophagy regulation and cancer progression.Apoptosis : an international journal on programmed cell death · 2025Review
- USP18 attenuates endoplasmic reticulum stress via the PERK-eIF2α-ATF4 axis to reduce apoptosis in hepatocellular carcinoma cells.Scientific reports · 2025Article
- Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer.Nature communications · 2025Article
- Chemical tools to define and manipulate interferon-inducible Ubl protease USP18.Nature communications · 2025Article
- Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells.Acta pharmaceutica Sinica. B · 2024Article
- Review
- Article
- Chemical tools to define and manipulate interferon-inducible Ubl protease USP18.bioRxiv : the preprint server for biology · 2024Article
- Deubiquitylating Enzymes in Cancer and Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis.Cancer biology & therapy · 2022Article
- Review
- Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer.ACS chemical biology · 2022Article
- Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARActa pharmaceutica Sinica. B · 2022Article
- The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth.Molecular cancer research : MCR · 2021Article
- TargetingCancers · 2021Review
- Advances in deubiquitinating enzymes in lung adenocarcinoma.Journal of Cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Lisa Maria MustachioDepartment of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Yun LuDepartment of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Laura J TafeDepartment of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Vincent MemoliDepartment of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Jaime Rodriguez-CanalesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Barbara MinoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pamela Andrea VillalobosDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ignacio WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hiroyuki KatayamaDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Samir M HanashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jason RoszikDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Masanori KawakamiDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kwang-Jin ChoDepartment of Integrative Biology and Pharmacology, The University of Texas McGovern Medical School, Houston, Texas.
John F HancockDepartment of Integrative Biology and Pharmacology, The University of Texas McGovern Medical School, Houston, Texas.
Fadzai ChinyengetereDepartment of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Shanhu HuDepartment of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Xi LiuDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sarah J FreemantleDepartment of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Ethan DmitrovskyDepartment of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. edmitrovsky@mdanderson.org.
Dartmouth–Hitchcock Medical Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTranslational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3MCenter for Molecular, Cellular, and Translational ImmunologyP30GM103415 · NIGMS · DARTMOUTH COLLEGE · PI GREEN, WILLIAM R · 2012 to 2015
$4.7MRETINOID CANCER PREVENTION MECHANISMSR01CA087546 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DMITROVSKY, ETHAN · 2000 to 2015
$4.1MTargeting Anaphase Catastrophe to Combat Lung CancerR01CA190722 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2015 to 2019
$1.8MK-Ras plasma membrane interactions: a tractable therapeutic targetR00CA188593 · NCI · WRIGHT STATE UNIVERSITY · PI CHO, KWANGJIN · 2017 to 2019
$747kK-Ras plasma membrane interactions: a tractable therapeutic targetK99CA188593 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHO, KWANGJIN · 2014 to 2015
$178kNCI NIH HHS K99 CA188593NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023108NCI NIH HHS R00 CA188593NCI NIH HHS R01 CA087546NCI NIH HHS R01 CA190722NIGMS NIH HHS P30 GM103415
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaAdenocarcinoma of LungAnimalsCarcinogenesisCell Line, TumorCell MembraneCyclin ECycloheximideDisease Models, AnimalEndopeptidasesFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansLung NeoplasmsMaleCyclin ECycloheximideEndopeptidasesKRAS protein, humanProto-Oncogene Proteins p21(ras)Ubiquitin ThiolesteraseUSP18 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.